Agenus Inc (AGEN)
5.22
+0.25
(+5.03%)
USD |
NASDAQ |
Apr 19, 15:56
Agenus Cash from Financing (TTM): 119.87M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 119.87M |
September 30, 2023 | 136.32M |
June 30, 2023 | 146.51M |
March 31, 2023 | 136.04M |
December 31, 2022 | 95.83M |
September 30, 2022 | 143.66M |
June 30, 2022 | 194.34M |
March 31, 2022 | 178.34M |
December 31, 2021 | 225.26M |
September 30, 2021 | 178.31M |
June 30, 2021 | 166.68M |
March 31, 2021 | 181.20M |
December 31, 2020 | 183.86M |
September 30, 2020 | 160.48M |
June 30, 2020 | 93.23M |
March 31, 2020 | 66.84M |
December 31, 2019 | 31.32M |
September 30, 2019 | 73.48M |
June 30, 2019 | 101.94M |
March 31, 2019 | 124.59M |
December 31, 2018 | 128.29M |
September 30, 2018 | 101.63M |
June 30, 2018 | 73.54M |
March 31, 2018 | 52.26M |
December 31, 2017 | 80.54M |
Date | Value |
---|---|
September 30, 2017 | 65.95M |
June 30, 2017 | 66.12M |
March 31, 2017 | 60.18M |
December 31, 2016 | -2.461M |
September 30, 2016 | -4.435M |
June 30, 2016 | 73.49M |
March 31, 2016 | 152.92M |
December 31, 2015 | 189.58M |
September 30, 2015 | 188.64M |
June 30, 2015 | 108.49M |
March 31, 2015 | 33.00M |
December 31, 2014 | 52.81M |
September 30, 2014 | 56.30M |
June 30, 2014 | 78.84M |
March 31, 2014 | 81.67M |
December 31, 2013 | 25.78M |
September 30, 2013 | 23.01M |
June 30, 2013 | 5.089M |
March 31, 2013 | 7.264M |
December 31, 2012 | 9.811M |
September 30, 2012 | 10.02M |
June 30, 2012 | 13.16M |
March 31, 2012 | 9.285M |
December 31, 2011 | 7.244M |
September 30, 2011 | 3.877M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
31.32M
Minimum
Dec 2019
225.26M
Maximum
Dec 2021
137.55M
Average
143.66M
Median
Sep 2022
Cash from Financing (TTM) Benchmarks
Protalix BioTherapeutics Inc | 24.67M |
InfuSystems Holdings Inc | -4.423M |
PAVmed Inc | 31.17M |
Allogene Therapeutics Inc | 95.70M |
Pfizer Inc | 26.07B |